Clinical Trial Update: A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating safety and tolerability of AG019 at different doses alone or with Teplizumab in adults with recent-onset type 1 diabetes; completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• AG019 (AG019)
• Teplizumab (Teplizumab)

Snippet

Sponsor: Precigen Actobio T1D, LLC | Conditions: Diabetes type1 | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-02-01